A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease
- Journal
- Nature Medicine
In The Last Decade
doi.org/10.1038/nm1239 →Countries where authors are citing A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease
This map shows the geographic impact of A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease more than expected).
Fields of papers citing A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease
This network shows the impact of A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease.
About A phase 1 clinical trial of nerve growth factor gene therapy for Alzheimer disease
This paper, published in 2005, received 780 indexed citations . Written by Mark H. Tuszynski, Leon J. Thal, Mary Pay, David P. Salmon, Hoi Sang U, Roy A.E. Bakay, Piyush M. Patel, Armin Blesch, H. Lee Vahlsing and Gilbert Ho covering the research area of Cellular and Molecular Neuroscience and Pharmacology. It is primarily cited by scholars working on Cellular and Molecular Neuroscience (396 citations), Molecular Biology (302 citations) and Physiology (247 citations). Published in Nature Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
This paper is also available at doi.org/10.1038/nm1239.